Enhanced expression of anti-apoptotic
B-cell lymphoma 2 (BCL-2)
protein is frequent in
cancer. Targeting of BCL-2 with the specific inhibitor
ABT-199 (
Venetoclax) has significant clinical activity in malignant diseases such as
chronic lymphocytic leukemia and
multiple myeloma. The small molecule drug
ABT-199 mimics the pro-apoptotic BCL-2 homology domain 3 of BH3-only
proteins and blocks the hydrophobic BC-groove in BCL-2. We have previously shown that
ABT-199 synergizes with the
proteasome inhibitor (PI)
bortezomib in
soft tissue sarcoma derived cells and cell lines to induce apoptosis. Synergistic apoptosis induction relies on the pore-forming effector BAX and expression of the pro-apoptotic BH3-only
protein NOXA.
Bortezomib augments expression of NOXA by blocking its proteasomal degradation. Interestingly, shown here for the first time, expression of NOXA is strongly enhanced by
ABT-199 induced integrated stress response (ISR). ISR
transcription factors ATF3 & ATF4 mediate transactivation of the BH3-only
protein NOXA which specifically inhibits the anti-apoptotic MCL-1. Thus, NOXA potentiates the efficacy of the BCL-2 inhibitor
ABT-199 by simultaneous inhibition of MCL-1. Hence,
ABT-199 has a double impact by directly blocking anti-apoptotic BCL-2 and inhibiting MCL-1 via transactivated NOXA. By preventing degradation of NOXA PIs synergize with
ABT-199. Synergism of
ABT-199 and PIs therefore occurs on several, previously unexpected levels. This finding should prompt clinical evaluation of combinatorial regimens in further
malignancies.